Compare Amgen, Inc. (AMGN) vs Nucor Corporation (NUE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Nucor Corporation — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Nucor Corporation trades at $225.91 (market cap $51.78B). The key difference: Amgen, Inc. is far larger — about 3.8× Nucor Corporation's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | NUE | |
|---|---|---|
Market Cap | $196.12B | $51.78B |
Sector | Health | Basic Materials |
52-Week High | $388.16 | $266.35 |
52-Week Low | $271.18 | $131.78 |
Enterprise Value | $241.41B | $56.42B |
Dividend Yield | 2.77% | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Nucor (NUE) trades at $227.37, up 2.29% today, with a bearish technical signal despite recent earnings beats. The stock shows mixed fundamentals with a P/E of 22.56 and net margin of 6.82%, while revenue has declined from $41.5B in 2022 to $32.5B in 2025. Recent news highlights a joint venture for AI power infrastructure and a 53-year dividend growth streak, supporting shareholder returns amid steel price volatility.
Outlook remains cautiously optimistic with a consensus price target of $262.89 (15.6% upside), driven by expansion projects and pricing strength. Risks include cyclical demand weakness and declining operating cash flow, but analyst sentiment is 59% buy-rated. The stock offers value through dividends and buybacks, though investors should monitor steel market dynamics and execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
